IBM Retirement Fund increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 69.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,836 shares of the biopharmaceutical company’s stock after acquiring an additional 13,070 shares during the quarter. IBM Retirement Fund’s holdings in Gilead Sciences were worth $2,518,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in GILD. Harel Insurance Investments & Financial Services Ltd. increased its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the period. Dubuque Bank & Trust Co. increased its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 267 shares during the period. Penserra Capital Management LLC increased its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. increased its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares during the period. Finally, American Beacon Advisors Inc. acquired a new position in Gilead Sciences in the first quarter valued at $143,000. Hedge funds and other institutional investors own 74.05% of the company’s stock.
In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at $7,318,327.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Over the last quarter, insiders sold 466,819 shares of company stock valued at $36,740,240. Corporate insiders own 1.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2017/09/17/gilead-sciences-inc-gild-shares-bought-by-ibm-retirement-fund.html.
Gilead Sciences, Inc. (GILD) opened at 82.36 on Friday. The firm has a market cap of $107.56 billion, a price-to-earnings ratio of 8.95 and a beta of 1.19. The stock has a 50 day moving average of $77.16 and a 200-day moving average of $70.20. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same period last year, the company posted $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, analysts expect that Gilead Sciences, Inc. will post $8.75 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.
A number of research analysts have commented on the stock. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Deutsche Bank AG restated a “buy” rating and issued a $81.00 price objective (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Royal Bank Of Canada assumed coverage on shares of Gilead Sciences in a research note on Thursday. They issued an “outperform” rating and a $94.00 price objective on the stock. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Finally, TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Eleven investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $83.79.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.